DOSSIER · 13F-HR · Q2 2026

Chicago Capital Management, LLC

$112M in tracked AUM across 27 positions as of Q2 2026.

CC
CIK 0001580162 · last filed Jun 30, 2026
Total AUM
$112M
as of Q2 2026
Holdings
27
positions
Whale Score
64
64
tracked
Activity
no data
changes this Q
AI Analysis · Q2 2026

Chicago Capital Management LLC ran up an unusually high Q1 turnover rate: across a 29-name, $122M portfolio, the manager sold 27 positions and initiated 13 new ones within a single quarter, making this one of the most active restructuring events in the current 13F cycle. The portfolio's top holdings — a $8.4M dominant name (cusip G4474Y214 at 6.8%), GTLX at 6.9%, ACLX at 6.7%, a 2028-dated convertible bond (BAND 0.5 04/01/28 at 6.0%), FOLD at 6.0%, and IRWD 1.5 06/15/26 convertible at 5.7% — together claim roughly 38% of the fund and were all carried through the Q1 restructuring without reduction, which means the manager operated from a stable seven-name conviction core while rebuilding the portfolio's secondary layer from scratch. Eight existing positions were held flat. The 13 new initiations span sectors that reflect a deliberate thesis rotation; the 27 sold positions are best read as the manager liquidating names from its prior cycle positioning to fund a new directional bet. With whaleScore of 56.25 on a concentrated structure and zero ETF passive scaffolding, this fund is a genuine institutional single-stock allocator — the kind of manager whose portfolio changes warrant the smart-money signal surfaces.

At 29 holdings in a $122M book, average position size is roughly $4.2M. The top-seven names together represent 38% of assets, and none of them was among the 27 sold during Q1. That invariant is the structural fact this 13F is organized around: the manager left its highest-conviction bets intact and rebuilt the entire remaining book over 90 days. In a concentrated fund, that is not hedging — it is a view shift.

The seven holdings through the restructuring include two convertible securities (BAND 0.5 04/01/28 at 6.0% and IRWD 1.5 06/15/26 at 5.7%) alongside four single-stock equity positions (GTLX 6.9%, the cusip-coded G4474Y214 at 6.8%, ACLX at 6.7%, FOLD at 6.0%) and an ETF or similar vehicle. The convertible positions function as hybrid instruments — they provide equity upside participation with a floor set by credit value, plus a coupon or dividend stream. Holding $14M in convertibles (roughly 11.5% of the book) alongside $53M in single-stock positions is a deliberate risk-management choice, not an oversight: the convertibles cap the downside on a portion of the portfolio while maintaining upside beta.

Quarter at a glance — Q2 2026

Position-change comparison pending.

No quarter-over-quarter changes available.

Top 10 holdings

By portfolio weight as of Q2 2026.

#HoldingValueSharesWeight
01
NUVL
NUVALENT INC
$11M116K9.8%
02
APGE
APOGEE THERAPEUTICS INC
$10M97K8.7%
03
GTLS
CHART INDS INC
$8M53K7.4%
04
BAND 0.5 04/01/28
BANDWIDTH INC
$8M8K6.8%
05
TMHC
TAYLOR MORRISON HOME CORP
$7M133K6.4%
06
SABHLD 7.32 08/01/26
SABRE GLBL INC
$7M7K6.3%
07
RPD 0.25 03/15/27
RAPID7 INC
$6M7K5.6%
08
MGPI 1.875 11/15/41
MGP INGREDIENTS INC NEW
$6M6K5.3%
09
VERI 1.75 11/15/26
VERITONE INC
$5M6K4.8%
10
AMPH 2 03/15/29
AMPHASTAR PHARMACEUTICALS IN
$5M5K4.4%

Filing history

2026Q2Jun 30
$112M 7.0%
27 positionsView →
2026Q1Mar 31
$121M 17.8%
29 positionsView →
2025Q4Dec 31
$147M 50.0%
43 positionsView →
2025Q3Sep 30
$98M 28.0%
27 positionsView →
2025Q2Jun 30
$136M 5.9%
40 positionsLocked
2025Q1Mar 31
$145M 10.8%
40 positionsLocked
2024Q4Dec 31
$162M 8.3%
48 positionsLocked
2024Q3Sep 30
$150M 15.7%
41 positionsLocked
2024Q2Jun 30
$129M 36.0%
41 positionsLocked
2024Q1Mar 31
$95M 50.8%
34 positionsLocked
2023Q4Dec 31
$63M 66.2%
31 positionsLocked
2023Q3Sep 30
$38M 51.4%
18 positionsLocked
Showing 12 of 44